Northern Trust Corp Acquires 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Northern Trust Corp raised its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 15.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 308,800 shares of the company's stock after buying an additional 42,302 shares during the period. Northern Trust Corp owned about 0.59% of Janux Therapeutics worth $16,533,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after buying an additional 442 shares in the last quarter. Avanza Fonder AB acquired a new position in Janux Therapeutics in the 4th quarter worth approximately $139,000. Meeder Asset Management Inc. acquired a new position in Janux Therapeutics in the 4th quarter worth approximately $159,000. Tower Research Capital LLC TRC boosted its stake in shares of Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock valued at $205,000 after buying an additional 3,436 shares during the period. Finally, Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics during the 4th quarter valued at $230,000. 75.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

JANX has been the subject of a number of recent research reports. Wedbush reiterated an "outperform" rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Scotiabank lowered their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Janux Therapeutics has a consensus rating of "Buy" and an average price target of $95.25.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. purchased 341,742 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the acquisition, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. This trade represents a 3.90% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,001 shares of company stock valued at $313,964. Company insiders own 8.10% of the company's stock.

Janux Therapeutics Price Performance

JANX traded down $0.26 during mid-day trading on Tuesday, hitting $23.92. The stock had a trading volume of 83,002 shares, compared to its average volume of 1,001,501. The stock's fifty day simple moving average is $28.50 and its 200-day simple moving average is $40.33. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -20.44 and a beta of 3.24. Janux Therapeutics, Inc. has a 1-year low of $22.48 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.